Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesMultianalyte Assays with Algorithmic AnalysesCPT cpt-81552-uveal-melanoma-15-gene-expression-risk-score
    Ask Trek AI about this page

    CPT 81552: mRNA Gene Expression Profiling, Uveal Melanoma Risk Score

    CPT code 81552 describes a laboratory service in which the lab performs technical mRNA gene expression profiling for 15 genes and executes an algorithmic analysis combining the patient data and test results to report a risk score for uveal melanoma metastasis; the service type is molecular pathology / gene expression profiling and the typical site of service is a clinical molecular pathology laboratory or reference diagnostic laboratory.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81552 policy alerts

    Get alerted when payer policies referencing 81552 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 62-year-old patient presents to an ophthalmic oncology clinic after enucleation of an eye for a primary uveal melanoma confirmed on histopathology. The ocular surgeon submits the formalin-fixed, paraffin-embedded tumor specimen or a dedicated tissue sample to a CLIA-certified molecular diagnostics laboratory for mRNA gene expression profiling. The laboratory performs 81552 testing: extraction of RNA, measurement of expression across a 15-gene panel, and application of a validated algorithm that integrates the gene-expression results with patient and tumor variables to generate a metastasis risk score. The lab returns a report indicating low- or high-risk of metastatic disease, which the ocular oncologist uses for prognosis counseling and surveillance planning. Typical site of service is an outpatient pathology/molecular laboratory receiving specimens from ambulatory surgical centers or hospital outpatient departments. Typical workflow steps: specimen collection and accessioning, specimen preparation and shipping (if off-site), laboratory technical processing (RNA extraction and expression assay), bioinformatic/algorithmic analysis, report generation, and secure transmission of results to the ordering ophthalmologist and inclusion in the patient’s medical record.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    88305Level IV surgical pathology, gross and microscopic examinationPerformed on enucleation or biopsy specimens prior to or alongside molecular testing to establish histopathologic diagnosis.
    88185Cytopathology, evaluation of fine needle aspiration, single specimenMay be used if FNA material is obtained for diagnostic cytology before or instead of excisional biopsy in ocular lesions.
    0000UData not available in the input.Data not available in the input.
    86341Immunoassay for tumor associated antigen; quantitativeAncillary tumor marker testing sometimes performed as part of workup; complements molecular risk profiling.
    G0452Data not available in the input.Data not available in the input.

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207P00000X
    207K00000X
    363L00000X
    175M00000X
    2279P1004X
    373H00000X
    207QA0401X
    103TM1800X

    Related ICD-10-CM Codes

    14 rows

    ICD-10-CM CodeDescription
    C79.49Secondary malignant neoplasm of other parts of nervous system
    C79.89Secondary malignant neoplasm of other specified sites
    C79.9Secondary malignant neoplasm of unspecified site
    D37.9Neoplasm of uncertain behavior of digestive organ, unspecified
    D48.7Neoplasm of uncertain behavior of other specified sites
    H35.051Retinal neovascularization, unspecified, right eye
    H35.052Retinal neovascularization, unspecified, left eye
    H35.52Pigmentary retinal dystrophy
    H54.7Unspecified visual loss
    R21Rash and other nonspecific skin eruption

    Showing 1–10 of 14

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-81490-RA-DISEASE-ACTIVITY-SCORE-SERUM-BIOMARKER-PANEL

    CPT 81490: Serum Biomarker Panel and RA Disease Activity Score

    CPT-81493-CORONARY-ARTERY-DISEASE-23-GENE-RT-PCR-RISK-SCORE

    CPT 81493: 23-Gene RT-PCR Molecular Test With CAD Risk Score

    CPT-81500-CA125-HE4-ALGORITHMIC-RISK-SCORE

    CPT 81500: Algorithmic Risk Score Using CA-125 and HE4

    CPT-81503-ALGORITHMIC-LAB-RISK-SCORE-CA125-APOLIPOPROTEIN-A1

    CPT 81503: Algorithmic Risk Score from Multiple Lab Markers

    CPT-81504-TUMOR-ORIGIN-RNA-EXPRESSION-CLASSIFIER

    CPT 81504: Tumor RNA Expression Profile Comparison

    CPT-81506-DIABETES-BIOMARKER-PANEL-WITH-RISK-SCORE

    CPT 81506: Diabetes Risk Score from Biochemical Assays

    CPT-81507-NIPS-CELL-FREE-DNA-TRISOMY-RISK-ANALYSIS

    CPT 81507: Noninvasive Prenatal Testing for Trisomies 13, 18, 21

    CPT-81508-PAPP-A-HCG-ALGORITHMIC-RISK-ASSAY

    CPT 81508: First-Trimester PAPP-A and hCG Risk Score

    CPT-81509-LAB-ALGORITHMIC-RISK-ASSESSMENT-PAPP-A-HCG-DIA

    CPT 81509: Prenatal Biochemical Risk Score from PAPP–A, hCG, DIA

    CPT-81510-PRENATAL-TRIPLE-MARKER-ALGORITHMIC-RISK-ASSESSMENT

    CPT 81510: Prenatal Serum Screening with Algorithmic Risk Score

    Showing 1–10 of 41

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.